Puma Biotechnology (PBYI) Receives a Hold from RBC Capital

RBC Capital analyst Kennen MacKay maintained a Hold rating on Puma Biotechnology (PBYI – Research Report) on January 24 and set a price target of $13.00. The company’s shares closed last Monday More »

Acceleron Pharma (XLRN) Gets a Hold Rating from RBC Capital

RBC Capital analyst Kennen MacKay maintained a Hold rating on Acceleron Pharma (XLRN – Research Report) on January 24 and set a price target of $47.00. The company’s shares closed last Monday More »